Dihydropyridine calcium channel blockers and renal disease

Nicolás R. Robles, Francesco Fici, Guido Grassi

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalHypertension Research
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Calcium Channel Blockers
Kidney
Chronic Renal Insufficiency
Mesangial Cells
Angiotensin Receptor Antagonists
Platelet Activating Factor
Platelet-Derived Growth Factor
Angiotensin-Converting Enzyme Inhibitors
Cell Proliferation
Blood Pressure
1,4-dihydropyridine

Keywords

  • Calcium channel blockers
  • Chronic kidney disease
  • Renal failure

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Dihydropyridine calcium channel blockers and renal disease. / Robles, Nicolás R.; Fici, Francesco; Grassi, Guido.

In: Hypertension Research, Vol. 40, No. 1, 01.01.2017, p. 21-28.

Research output: Contribution to journalReview article

Robles, Nicolás R. ; Fici, Francesco ; Grassi, Guido. / Dihydropyridine calcium channel blockers and renal disease. In: Hypertension Research. 2017 ; Vol. 40, No. 1. pp. 21-28.
@article{466dc806445c48349b23ffed190a60a9,
title = "Dihydropyridine calcium channel blockers and renal disease",
abstract = "Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.",
keywords = "Calcium channel blockers, Chronic kidney disease, Renal failure",
author = "Robles, {Nicol{\'a}s R.} and Francesco Fici and Guido Grassi",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/hr.2016.85",
language = "English",
volume = "40",
pages = "21--28",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Dihydropyridine calcium channel blockers and renal disease

AU - Robles, Nicolás R.

AU - Fici, Francesco

AU - Grassi, Guido

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.

AB - Although blood pressure control is considered the main mechanism for preventing the progression of chronic kidney disease (CKD), angiotensin-converting enzyme inhibitors and angiotensin receptors blockers have an additional organ-protective role. The effects of calcium channel blockers (CCBs) in renal disease are not so clearly defined. CCBs have pleiotropic effects that might contribute to protection of the kidney, such as attenuating the mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors and suppressing mesangial cell proliferation. Some evidence has accumulated in recent years demonstrating that the new dihydropyridinic CCBs (such as lercanidipine or efonidipine) may affect both postglomerular and preglomerular vessels, resulting in a decreased filtration fraction and nephroprotective effect. Increasing clinical and experimental evidence supports this view and the use of CCBs in CKD hypertensive patients.

KW - Calcium channel blockers

KW - Chronic kidney disease

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=85008319317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008319317&partnerID=8YFLogxK

U2 - 10.1038/hr.2016.85

DO - 10.1038/hr.2016.85

M3 - Review article

AN - SCOPUS:85008319317

VL - 40

SP - 21

EP - 28

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -